Clinical Trial

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Recruiting → Completed 2025-12-24
Trial Details
NCT Number NCT07253324
Lead Sponsor Engrail Therapeutics INC
Conditions Major Depressive Disorder
Enrollment 48 participants
Start Date 2025-02-17
Primary Completion 2025-11-26 (estimated)
Study Completion 2025-11-26 (estimated)
Updated on ClinicalTrials.gov 2025-12-31